- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Immunotherapy: Where Is It At? Where Is It Headed?
Panelists Daniel J. George, MD, and Jeffrey Weber, MD, PhD, believe that while immunotherapy is still relatively new, this therapy option will play a promising role in the future for the treatment of cancer.
Immunotherapy is the most exciting area in cancer research right now, declares Dr George.
Dr George credits the IMPACT trial as a pivotal trial that led to the approval of Provenge, the first cellular immunotherapy approved by the FDA for the treatment of metastatic prostate cancer, and elaborates on the PSA quartile trial. He explains how the benefits of trials, in terms of overall survival and long-term disease-free survival with checkpoint inhibitors, help immunotherapy gain credibility for the treatment of cancer.
Dr Weber continues by highlighting current key trials featured during the ASCO 2013 meetings, which include trials for PD-1 antibodies, ipilimumab, and new combinations of ipilimumab with granulocyte-macrophage colony-stimulating factors (GM-CSFs).
George hopes that the results of key trials will help change the population of patients who can be treated with immunotherapy, as well as help providers treat patients in a more precise manner.
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
